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1. Introduction 
The past four decades have witnessed the evolution of liver transplantation exploration 
procedures, and whilst they had witnessed a high mortality and morbidity they now serve 
as a successful therapeutic measure for end-stage liver disease. Nowadays, one year and five 
years survival for elective cases are often in excess of 85%-88% and 70%-75% and with an 
excellent quality of life (Annals of Hepatology, 2010). The remarkable success of liver 
transplantation is due largely to the development of immunosuppressive regimens that are 
highly effective at protecting allografts from acute rejection, and which ensure their survival 
in most cases. Interestingly, early liver transplantation studies with out-bred swine 
demonstrated that a high percentage of recipients maintained their graft in the absence of 
immunosuppression (Calne R Y et al., 1969). Subsequently, the spontaneous tolerance of 
liver allografts was also shown in liver transplantation in several allogeneic rat strain 
combinations and in most allogeneic mouse strain combinations (Farges O et al., 1995; 
Dresske B et al., 2002). As such, and compared with other solid-organ transplants, liver 
allografts have long been considered to be immunologically privileged, as manifest by an 
absence of hyperacute rejection despite a positive T cell cross-match, a low incidence of graft 
loss due to chronic rejection, and the potential for hepatocyte regeneration after tissue 
injury. Finally, in clinical transplantation, there is increasing evidence that some liver 
transplant recipients who cease taking immunosuppressive drugs maintain allograft 
function. Despite this special status, the liver can display destructive immunologic 
processes, since acute liver allograft rejection occurs in approximately 50% to 75% of liver 
transplant recipients (although in the majority of cases it is readily reversed with 
immunosuppressive approaches tailored to treat cellular rejection) (covered in a separate 
CAQ corner). Immunosuppressive drugs, however, also produce significant toxic effects 
that increase patient morbidity and mortality (Lechler R I et al., 2005; Sayegh M H et al., 
2004). Moreover, the current immunosuppressive regimens do not prevent the development 
of chronic rejection, which is a major cause of graft loss. Most studies have also shown that a 
variety of autoimmune diseases with unknown aetiologies target the liver, including 
primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis, and biliary 
atresia (Duclos-Vallee J C et al., 2009; Schramm C et al., 2010; Guichelaar MM et al., 2003). 
As such, compared with other solid-organ transplants, liver transplantation is complex, 
having a sometimes paradoxical interaction with the host immune system. Understanding 
www.intechopen.com
 
Liver Transplantation – Basic Issues 
 
76 
these mechanisms is important, as it aids in the understanding of the clinical features of 
rejection and – hence – in making an early diagnosis and delivering appropriate treatment. 
Knowledge of these mechanisms is also critical in developing strategies to minimise 
rejection and in developing new drugs and treatments that blunt the effects of the immune 
system on transplanted organs, thereby ensuring the longer survival of these organs. The 
next chapter will elaborate on various aspects of liver transplantation immunology. 
2. Types of grafts 
Grafts of different species can cause different degrees of immune response to recipients. 
Generally, the  greater the difference between the species, the more likely that it is that there 
will be a stronger immunological rejection. Accordingly, this section will discuss the types 
of graft. Liver grafts often mainly consist of four types: autograft, isograft, allograft and 
xenograft (Figure 1). The definitions and features of all grafts will be now be described in 
detail and the effects of different grafts on the body's immune system also will be 
introduced.   
 
Fig. 1. Types of grafts 
2.1 Autograft and isograft  
Autograft means ‘self-tissue’ and refers to where on organ is transferred from one body site 
to another within the same individual. In recent years, auto-liver transplantation has been 
operated in some centres, but the number does not exceed one hundred because the 
operation technique is very complex and difficult. The autograft is a promising graft and has 
two advantages: (1) the graft is a tissue or organ already belong to the recipient who has 
spontaneous tolerance to the graft and so may avoid taking immunosuppressive drugs;  
(2) liver shortage is rapidly becoming a major restricting factor on the development of liver 
transplantation, and autografts avoid this problem. An isograft is a tissue or organ which is 
transferred between genetically identical individuals, e.g., liver transplantation between 
identical twins or grafts between mice of the same in-bred strain. This graft has the same 
advantages as the autograft, and it is not necessary to apply immunosuppressive regimens 
to the recipients. In particular, with the development of living donor liver transplantation, 
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this is an excellent graft. Nevertheless, the isograft is fairly uncommon and far from 
universal.   
2.2 Allograft  
An allograft is a tissue or organ which has been transferred between genetically different 
members of the same species. Allografts account for many human transplants, including 
those from cadaveric, living-related and living-unrelated donors. It is also called an 
allogeneic graft or a homograft. With regard to liver transplantation, most grafts are 
allografts. The graft may cause acute rejection and chronic rejection, and as such surgeons 
have to select the optimal match so as to reduce the occurrence of rejection by the ABO 
group and the HLA system.  
2.3 Xenograft 
A xenograft is a tissue or organ which has been transferred between different species. Donor 
shortage imposes the main restricting factor on liver transplantation and the continual 
growth of transplantation has led to significant organ shortages for a long time. At present 
in China – which is a country with a high incidence of liver disease – almost 3,000,000 
patients develop some degree of liver cirrhosis, and about 10% of patients deteriorate to 
end-stage liver cirrhosis or liver cancer. As such, clinicians are often faced with the difficult 
prospect of rationing organs. Furthermore, liver transplantation in urgent cases is usually 
delayed – occasionally with fatal outcomes – until a suitable liver becomes available. Using 
animals as liver donors is a theoretically attractive solution, because it offers a potentially 
inexhaustible source of liver. This is of particular relevance for patients with fulminant liver 
failure who require urgent transplantation. Another potential use of xenografts lies in the 
fact that some animals are immune to certain viruses which may re-infect a human liver 
transplant (hepatitis being a case in point). Xenografts have been applied in the clinical 
region. Starzl's team transplanted two baboon livers into human subjects at Pittsburgh 
(Starzl et al., 1993). Although they did so with good graft function (and this may well result 
in the further development of this approach) the graft is confronted with some problems. 
The first is a problem of theory, such that only about fifty-percent of people support 
xenotransplantation. The second – and the biggest – problem is one of rejection, since 
xenotransplantation often causes hyperacute rejection and leads to graft dysfunction.  
3. Immunological basis of allograft rejection 
With regard to liver transplantation, grafts mainly originate from different members of the 
human species. The genetically encoded immunologically mediated barrier to 
transplantation was recognised and defined over the course of the last century. The 
immunological study of transplantation has played a pivotal role in the development of 
clinical transplantation. Although the first successful liver transplant was between identical 
twins, the development of transplantation as an important facet of modern medical therapy 
required the introduction of immunosuppression so as to prevent and treat the rejection of 
allografts (Liu L U et al., 2002; Yoshizawa A et al., 2006; Braillon A, 2009). The process of 
rejection is very complicated and has been shown to be caused by transplantation antigens, 
including major histocompatibility antigens, minor histocompatibility antigens and other 
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alloantigens. In addition, infiltrating leucocytes also launch the process, and it exhibits 
specificity and memory and is prevented by lymphocyte depletion (Gowans J L, 1962). The 
major histocompatibility complex (MHC) was identified as encoding the dominant 
transplantation antigens, and these were shown to be identical to serologically defined 
human leucocyte antigens (HLA), and subsequently to the elements responsible for the self-
restriction of immunological responses to conventional antigens. The molecular and cellular 
basis of graft rejection will be described in the next section (Figure 2).  
Liver failure
APC
Donor liver
T cell, lymphocytes
Cell activation
Cytokines
rejection
 
Fig. 2. The evolution of the immune response after liver transplantation. MHC, major 
histocompatibility complex; TCR, T cell receptor; APC, antigen presenting cell; IFN, 
interferon; TNF, tumour necrosis factor 
3.1 Cell-mediated rejection of allografts  
After liver transplantation, antibody-mediated, hyperacute vasculitic rejection can occur in 
individuals with preformed antibodies against the donor's MHC class I–encoded antigens. 
Under most other circumstances, acute allograft rejection is initiated by the large number of 
recipient T cells that recognise donor alloantigens (Stefanova I et al., 2003). Thus, the 
transplantation of MHC histoincompatible tissues elicits a strong, cytopathic, T cell-
dependent immune response to donor tissues. By the T cell-dependent pathway to rejection, 
graft alloantigens are processed by specialised antigen presenting cells (APCs). Graft MHC 
molecules are internalised by donor and recipient APCs (Figure 3), following intracellular 
processing, and MHC peptide fragments are presented to the recipient’s T cells 
(Watschinger B, 1995; Afzali B et al., 2008). Antigen presentation involves the engagement of 
these peptide antigenic fragments within a groove on the MHC molecules of the APC 
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surface. Acute cellular rejection is the best-characterised graft-specific form of immune 
rejection. Clinically apparent acute cellular rejection is defined by an often-sudden 
deterioration in allograft function; biopsy analysis of the transplanted tissue shows 
infiltration by host T cells and other mononuclear leucocytes and signs that these infiltrating 
cells have damaged the graft. Despite the routine use of immunosuppressive therapy, acute 
rejection is not rare. Studies show that CD4 and CD8 T cells both participate in acute 
rejection, although the rejection response is mediated primarily by CD4 T cells. CD4 T cells 
are activated by the above direct and indirect pathways, and primarily mediate the rejection 
response (Watschinger B., 1995). Although CD4 T cells are important in rejection, many 
activated CD8 T cells infiltrate the transplant tissue at the time of rejection, along with other 
mononuclear leucocytes (Strom TB et al., 1975). The cells of the innate immune system, such 
as natural killer (NK) cells, are also present in allografts during rejection. NK cells can 
recognise alloantigens because they constitutively express inhibitory receptors that are 
specific for self-MHC class I antigens; in addition, cytokines secreted by activated CD4 or 
CD8 T cells can promote the activation of NK cells, which can initiate and aggravate the 
rejection response (Dollinger MM et al., 1998).  
Graft
A. Direct 
pathway
B. indirect 
pathway
Donor APC Recipient APC
MHC MHCTCR TCR
T cell T cell
 
Fig. 3. Pathways of alloantigen presentation. (A) In the direct pathway, recipient T cells 
recognise intact allogeneic MHC molecules on the surface of donor APCs. The direct 
pathway is responsible for the large proportion of T cells that have reactivity against 
alloantigens due to the cross-reactivity of the T cell receptor (TCR) with self and foreign 
MHC molecules. (B) In the indirect pathway, recipient APCs trafficking through the 
allograft phagocytose allogeneic material are shed by donor cells (mostly peptides derived 
from allogeneic MHC molecules) and presented to the T cells on recipient MHC molecules 
3.2 Humoral-mediated rejection of allografts 
The humoral immune response is also important in the mediation of allograft rejection. The 
production of anti-donor MHC antibodies is associated with acute and chronic graft 
damage, usually in the form of graft vasculopathy. These antibodies can damage the graft 
by activating complement and mononuclear cells with Fc receptors that recognise the heavy 
chain of antibodies. Thus, Fc receptor–expressing leucocytes can be activated by antibody-
coated donor cells. Anti-donor antibodies can also directly inhibit signalling cascades within 
endothelial cells (Li F et al., 2009). Humoral-mediated rejection of allografts is often 
observed following kidney, heart and lung transplantation, but liver allografts appear to 
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recover in relation to the development of humoral-mediated rejection. Most transplant 
organs manifest insidious and inexorable dysfunction as time passes. Although this process 
was formerly called ‘chronic rejection’, it is not clear that donor-specific immune rejection is 
the sole or even the primary cause in many conditions (Seetharam A et al., 2010). Pathology 
analysis often reveals fibrosis and atrophy in the absence of infiltration by T cells and other 
mononuclear leucocytes. Potential additional causes for chronic allograft failure include 
viral infection, recurrence of the original disease and drug toxicity. In general, humoral-
mediated rejection of allografts is relatively uncommon in liver transplantation. 
3.3 Memory T cell mediated rejection of allografts 
Following T cell activation and proliferation, homeostasis of the adaptive immune system is 
restored by cell death – via “neglect” – of most antigen-specific T cells. A small number of T 
cells, however, survive and become long-lasting memory cells that ensure protective 
immunity against pathogens. Memory T cells can be divided into central memory and 
effector memory subsets, based on their circulation pattern and functional responsiveness. 
With regard to organ transplantation, upon re-exposure to donor antigens donor-reactive 
memory T cells are more sensitive to antigens, function more rapidly, produce effector 
cytokines, survive longer than naïve T cells and directly or indirectly produce cytolytic 
effects on the transplanted tissue (Ku C C et al., 2000; Sallusto F et al., 2000; Garcia S et al., 
1999 & Barber DL et., 1999). Central memory T cells are responsible for recall antigen 
responses, and effector memory T cells survey peripheral tissues and immediately respond 
to invading pathogens (Sallusto F et al., 2004). As a consequence of continuous exposure to 
foreign antigens, memory T cells accumulate with time and represent approximately 50% of 
the total T cell pool in adults. Recipients who have not received a transplanted graft can still 
generate donor-reactive T cells, which can appear through immunisation by direct exposure 
to alloantigens via pregnancy or blood transfusion (Bingaman A W et., 2002). Furthermore, 
donor-reactive memory T cells can be generated in the absence of alloantigen exposure 
through heterologous immunity. Some memory T cells are therefore primed by an antigenic 
pathogen-derived peptides and cross-react with allogeneic peptides presented by the self or 
the donor MHC molecules. Alloreactive naïve T cells can acquire a memory phenotype and 
generate a substantial pool of donor-reactive memory T cells after transplantation, even 
when a recipient is under immunosuppressive therapy. Furthermore, the use of antibodies 
that deplete host T cells can amplify this phenomenon by inducing homeostatic T cell 
proliferation in response to lymphopenia (Wu Z et al., 2004). Because of their capacity to 
rapidly generate effector immune responses upon rechallenge, memory T cells appear to be 
particularly efficient at mediating allograft rejection (Zheng X X et al., 1999 & Schenk A D et 
al., 2008). In addition, memory T cells are less sensitive than naïve T cells to many 
immunosuppressive strategies. Compared with conventional T cells, memory T cells are less 
sensitive to T cell-depleting antibodies and therapeutics that block the CD28 and CD154 co-
stimulatory signallers which inhibit the mammalian target of rapamycin (Pearl J P et al., 
2005; Vu M D et al., 2006; Adams A B et al., 2003 & Araki K et al., 2009). The effects of 
memory T cells on the allograft response have been well delineated in animal models of 
allograft tolerance, wherein the generation of memory T cells by pre-sensitisation, 
heterologous immunity or homeostatic proliferation prevents the graft-protecting effects of 
most tolerising therapeutic strategies (Koyama I et al., 2007 & Valujskikh A et al., 2002). In 
contrast to human recipients, animals live in the protected environments of transplantation  
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laboratories and do not usually contain substantial numbers of memory T cells. This is one 
of the reasons that may explain the difficulties of translating into the clinic the results of 
protocols capable of creating allograft tolerance in rodent models. But the results cannot be 
applied in clinical conditions. Given the lower efficacy of conventional immunosuppressive 
drugs on activated memory lymphocytes, it is not surprising that memory T cells also exert 
harmful effects in clinical transplantation. In transplant studies, it is clearly understood that 
memory T cells – however they are generated – pose a significant barrier to inducing 
tolerance to allografts (Chalasani G et al., 2002; Zhai Y et al., 2002 & Adams AB et al., 2003). 
Thus, a better understanding of how to target this cell population and the designing novel of 
therapies that inhibit these cells would be beneficial.   
3.4 Co-stimulatory pathways and the immunology of allografts 
Evidently, T cells must receive two distinct but coordinated signals in order to achieve 
optimal activation. The first signal is provided by the TCR engagement with recognition of 
peptide/ MHC I or II on APCs, and the second signal is achieved by the interaction of co-
stimulatory molecules on the T cells and their ligands on APCs. The importance of co-
stimulation was found through experimental models in which its inhibition was achieved by 
some means, Signal 1 in the absence of signal 2 – as likely occurs in the liver – leads to a state 
of T cell non-responsiveness (or anergy) in which T cells can recognise cognate antigens 
through the TCR, but fail to mount a functional response upon reencounters with the 
antigen. So, there have been significant efforts to inhibit or block co-stimulatory pathways as 
a means of achieving allograft tolerance. There are two co-stimulatory pathways that are 
important in the generation of a complete T cell response are CD28/B7 and CD40/CD154 in 
the co-stimulatory field. 
The role of CD28 has perhaps been that most intensively investigated in the co-stimulatory 
field. CD28 represents the prototypical T cell co-stimulatory molecule. In humans, CD28 is 
expressed on 90% of CD4 T cells and 50% of CD8 T cells; moreover, ligands for CD28, B7-1 
(CD80) and B7-2 (CD86) are found on a variety of APCs including DCs, B cells and 
macrophages. The expression of CD86 is greater than for CD80 on APCs, although CD80 
expression is enhanced during APC activation. The expression of CD80 and CD86 has been 
examined by immunohistochemistry or real-time polymerase chain reaction in livers 
following transplantation (Kwekkeboom J et al., 2003). CD80 was expressed only 
sporadically on normal liver but was present on at least 25% of the Kupffer cells in 45% of 
the transplanted livers. CD86 was found on the majority of Kupffer cells in all transplanted 
liver tissue and in normal liver tissue. The effect of ligation of CD28 by either CD86 or CD80 
appears to be increased cytokine synthesis and proliferation by various intracellular 
signalling. Immunohistochemical analysis of CD86 expression in biopsies of liver recipients 
demonstrated an association with the increased expression of CD86 in the graft during 
severe acute cellular rejection (Bartlett A S et al., 2003). CTLA4 (CD152) is a CD28-related 
protein that binds to CD86 and CD80. Whereas CD28 delivers a positive co-stimulatory 
signal to T cells, CD152 delivers a negative signal that attenuates T cell function. CD152 
expression is enhanced after T cell activation, and it has a higher affinity for CD86 or CD80 
than does CD28; it has been proposed that the physiologic function of CD152 is to 
downregulate T cell responses. Therefore, specific activation of CD152 could potentially 
yield immunoinhibitory function and achieve allograft tolerance, but this ideal approach has 
been reached by the lack of suitable reagents. 
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The CD40/CD154 co-stimulatory pathway is a second important co-stimulatory pathway 
that is critical in the immune response of allotransplantation. CD40 is mainly expressed on 
APCs (including DCs, B cells, and macrophages) but it can also be expressed on nonimmune 
cells (including endothelial cells, mast cells, platelets and epithelial cells). However, CD154 
is mainly expressed on CD4 T cells following activation, and to a lesser extent on NK cells, B 
cells, and CD8 T cells. CD154 combines with CD40, which is critical for the activation of 
DCs, B cells, and macrophages. In DCs, CD40 upregulates interleukin12 (IL-12) production, 
and in macrophages it results in the production of various proinflammatory cytokines. 
CD154 was also detected on Kupffer cells and on sinusoidal macrophages in livers during 
chronic rejection, but not in stable liver allografts or normal liver (Gaweco A S et al., 1999). 
The most widely-used measure to block CD28-B7 interactions has been CTLA-
immunoglobulin (Ig). In the orthotopic rat liver transplantation model, repeated 
administration of CTLA-Ig – beginning with CTLA-Ig in combination with donor splenocytes 
– leads to extended graft survival of >100 days, whereas the delayed administration of 
CTLA4-Ig alone or donor splenocytes alone did not (Neumann U P, et al., 2002). In recent 
years, many studies have shown that B7 cross-linking on APCs by CTLA4-Ig induces 
indoleamine 2, 3-dioxygenase (IDO), which itself inhibits local T cell activation (Mellor A L 
et al., 2003; Li W et al., 2009). Gene therapy approaches to deliver CTLA4-Ig to liver 
allografts have been successfully used in some animal experiments. Adenoviral-mediated 
gene delivery of CTLA4-Ig through ex vivo perfusion of cold preserved livers resulted in 
indefinite survival of rat liver allografts and in the generation of donor-specific 
unresponsiveness (Olthoff K et al., 1998). An interesting report suggests that CD154/CD40 
interaction plays a role in promoting dendritic cell-maturation in the absence of 
CD4+CD25+ regulatory lymphocytes, whilst these cells promote the maintenance of 
immaturity (Serra P et al., 2003; Misra N et al., 2004). This accounts for the importance of DC 
activation, not only by innate immune mechanisms but also by activated T cells. The efficacy 
of anti-CD154 in a rat liver allograft model not only prolongs allograft survival but it was 
also associated with fewer complications (Bartlett AS et al., 2002). These roles underline the 
significant beneficial effects of CTLA4-Ig and anti-CD154 in pre-clinical models of 
transplantation; however, its clinical application has a long way to go for liver transplantation. 
4. Classification and effector mechanisms of allograft rejection 
Allograft rejection mainly involves host-versus-graft reaction in liver transplantation, which 
is the rejection of the transplant by the recipient's body. The recipient's lymphocyte 
mediated reactions to allogeneic or xenogeneic cells – acquired as a graft or otherwise –lead 
to damage and/or the destruction of the grafted cells. The graft rejection has been divided 
into three groups: hyperacute rejection, acute rejection and chronic rejection (Table 1). 
Type of rejection Time taken Cause 
Hyperacute Minutes-hours Pre-existing anti-donor antibodies and complement 
activation 
Acute Days – weeks Primary activation of T cells 
Chronic Months – years Causes unclear: antibodies, slow cellular reactions, 
immune complexes, recurrence of disease. 
Table 1. Different types of graft rejection 
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4.1 Hyperacute rejection 
Hyperacute rejection often occurs within minutes to hours after the host blood vessels are 
anastomosed to graft vessels. The rejection is mediated by pre-existing antibodies specific to 
the graft antigens (including ABO blood type antigens, VEC antigens and HLA antigens). 
Furthermore, these different antigens can activate the complement of the host and lead to 
damage to the endothelial cell. Studies have reported that the process is often accompanied 
with platelets activation and results in thrombosis and vascular occlusion (Fiane A E et al., 
1999). In addition, the massive recruitment of neutrophils occurs, followed by rapid 
inflammation after transplantation. The pathological changes of hyperacute rejection are 
thrombotic occlusion of the graft vasculature ischemia, denaturation and necrosis (Figure 4). 
This rejection is relatively rare in liver transplantation. 
 
Fig. 4. Hyperacute rejection: complement activation, endothelial damage, inflammation, 
thrombosis and vascular occlusion 
4.2 Acute rejection 
Acute rejection occurs within days and up to three months after transplantation (80-90% of 
cases occur within one month). The rejection occurs due to donor HLA interaction with the 
host T cells, creating a cascade of immune responses initiated by that interface. After a solid 
organ transplant, there is an immunological milieu of activity. The mechanisms of the 
process involve abundant immune factors, such as humoral and/or cellular mechanisms 
(Figure 5). Antibodies can injure the graft by activating complement and mononuclear cells 
with Fc receptors that recognise alloantigens on the endothelial cell, resulting in vasculitis. 
Cytotoxic T cells (CD8+) will recognise alloantigens on an antigen presenting cell (APC) by 
direct presentation on the donor tissue and endothelial cells, which promotes the apoptosis 
of transplanted tissue. It has been shown that CD8+ cells alone are sufficient for the 
mediation of acute allograft rejection, but with the help of CD4+ cytokines secretion – such 
as IL-2 – clonal expansion and the expression of cytotoxic attack molecules will be 
upregulated (Kreisel D et al., 2002). The Fas/Fas ligand (FasL) pathway is another death-
inducing pathway which is utilised by CD8+ cells. Whereas FasL is specifically induced 
upon CD8+ cells’ activation, Fas is ubiquitously expressed on lymphoid and non-lymphoid 
tissue, including the liver. The Fas/FasL pathway is thought to play an important role in a 
variety of hepatic pathologies, and there is evidence that this pathway is also active during 
liver allograft rejection (Tannapel A et al., 1999; Ogura Y et al., 2001). Delayed 
hypersensitivity also has an important role in acute rejection, being initiated by alloantigen-
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primed CD4+ cells specific to the donor class II (Carrodeguas L et., 1999). CD4+ cells release 
IFN-γ by re-exposure to specific alloantigens, a proinflammatory cytokine that can cause the 
activation of macrophages and the subsequent release of a variety of inflammatory 
mediators. These inflammatory mediators can augment the cellular anti-graft response or else 
can cause direct tissue damage. The acute rejection relatively occurs after liver transplantation 
is rare. But it has been a challenging process to try to unravel the participation of specific 
effector pathways and their interrelationships in the acute rejection of liver transplantation. 
The pathological features of acute rejection are acute vasculitis and parenchymal cell 
necrosis, along with the infiltration of lymphocytes and marophages (Figure 6).  
 
Fig. 5. Acute rejection: parenchymal cell damage and endotheliitis 
 
Fig. 6. A higher magnification of the previous photomicrograph details the subendothelial 
localisation of lymphocytes and the slight extension of the infiltrate into the perivenular 
hepatic parenchyma (http://tpis.upmc.com/TPIShome/) 
4.3 Chronic rejection 
Chronic rejection is less well-defined than either hyperacute or acute rejection, developing 
months or years after acute rejection reactions have subsided. Chronic rejection is an 
indolent but progressive form of allograft injury that is usually irreversible and which 
eventually results in the failure of most vascularised solid organ allografts. It is the single 
most significant obstacle to morbidity-free long-term survival. By five years after 
transplantation, it affects as many as 30-50% of heart, lung, pancreas and kidney allograft 
recipients, but only 4-8% of patients who undergo liver replacement (Demetris, A J et al., 
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1997). Liver allografts differ from other solid organs in that chronic rejection is potentially 
reversible. This feature has been mainly attributed to its unique immunobiological privilege 
and the regenerative capacity of the process. Livers with chronic rejection have a decreased 
number of bile ducts on biopsy. This is referred to as "vanishing bile duct syndrome" 
(Demetris A et al., 2000). Chronic rejection is characterised by vasculopathy, fibrosis and a 
progressive loss of organ function. It is probably caused by multiple factors, viz., antibodies 
as well as lymphocytes (Figure 7). Chronic rejection may be mediated by a low-grade, 
persistent, delayed hypersensitivity response in which activated macrophages secrete 
mesenchymal cell-growth factors. Of potential importance are the persistent viral infections 
which induce cellular immune responses which in turn may synergise with donor-specific 
alloreactive T cells within the allograft. Chronic rejection may also reflect chronic ischemia 
secondary to the injury of blood vessels by antibody or cell-mediated mechanisms. Vascular 
occlusion may also occur as a result of smooth muscle cell proliferation in the intimae of 
arterial walls. 
 
Fig. 7. Severe or very late-stage chronic rejection can result in the loss of the small branches 
of the hepatic artery, in addition to the loss of bile ducts. Note the lack of bile ducts and lack 
of hepatic artery branches in this portal tract (http://tpis.upmc.com/TPIShome/) 
5. Prevention and treatment of allograft rejection 
Allograft rejection is prevented by graft selection before transplantation, such as ABO blood 
group and HLA matching. Treatment of allograft rejection refers to immunosuppressive 
therapy, involving an immunosuppressive drugs selection and regimen, molecular therapy 
and cellular therapy.  These related factors will be briefly described in this section. 
5.1 Graft selection 
The majority of liver transplant centres regard blood group compatibility as the primarily 
immunological selection criterion. A liver from a donor with a compatible ABO and Rh 
blood group is easy and feasible, with well-documented reports of this being performed in 
urgent situations (Gordon R D et al., 1986). In recent years, many transplantation centres 
have also carried out the operation with ABO-incompatible grafts, and the outcomes of 
ABO-incompatible liver transplantations have been similar to that of blood-type-matched 
transplantations in some centres. However, infection is the major cause of morbidity and 
mortality after ABO-incompatible liver transplantation (Tanabe M et al., 2010). At present, 
the transplantation of compatible but not identical livers is common practice, especially for 
www.intechopen.com
 
Liver Transplantation – Basic Issues 
 
86 
recipients with the less common blood groups. Interestingly, the results of ABO identical 
grafts were slightly better than the ABO compatible but non-identical grafts (Gugenheim J et 
al., 1990). An occasional complication with compatible, non-identical grafts is the occurrence 
of allograft rejection, due to the immunocompetent passenger lymphocytes within the 
transplanted liver producing antibodies against the recipient erythrocytes. It is well-
established that renal transplantation in the presence of donor-specific cytotoxic antibodies – 
demonstrated by a positive cross-match – will result in rapid graft loss. However, the liver 
behaves in a totally contrary manner. In addition, the major histocompatibility antigens 
have a well-documented role in renal transplantation. However, early studies of liver 
transplantation in pigs implied that the liver may be a privileged organ exhibiting minimal 
rejection, with some grafts surviving without immunosuppression. This special feature 
prompted surgeons to ignore HLA-matching in patient selection for donor shortages. 
Retrospective data has not shown any clear survival advantages associated with good HLA-
matching (Navarro V et al., 2006). Interestingly, some studies suggest that there is a clear 
disadvantage with certain aspects of HLA-matching. The largest series from Pittsburgh, 
involving more than 500 transplants, concludes that overall graft survival is actually 
reduced in grafts matched for HLA (Markus BH et al., 1988). 
5.2 Immunosuppressive therapy 
The liver is a privileged organ with a lower incidence of rejection than other organs, but 
immunosuppressive regimens are nonetheless required to control the alloreactive T-
lymphocyte response after transplantation. In the 1990s, acute liver rejection occurred in up 
to 60% [1] of patients, without compromising graft or and patient survival (Neuberger J, 
1999). Since 2000, the incidence of acute liver rejection has decreased to 15% of recipients. 
The incidence of chronic rejection is also declining, and most centres report current rates of 
4% to 8%, whereas in the 1990s, rates of 15% to 20% were observed (Neuberger J, 1999).This 
decrease correlated with the use of new immunosuppressive drugs and improvements in 
treatment-management. 
Over the last three decades, the number and types of immunosuppressive agents available 
to clinicians have increased considerably. The immunosuppressive therapy used in liver 
transplantation includes agents such as corticosteroids, calcineurin inhibitor (CNI), 
antimetabolites, inhibitors of TOR, and monoclonal and polyclonal antibodies which have 
different patterns of action (Figure 9) (Beaudreuil S et al., 2007). Corticosteroids are a class of 
steroid hormones that are produced in the adrenal cortex. Corticosteroids are involved in a 
wide range of physiological systems, including stress-response, immune-response and the 
regulation of inflammation. The drugs are hydrophobic, which enables them to enter the cell 
by membrane diffusion. They then form complexes with cytosolic receptors, leading to their 
translocation to the nucleus where they bind to glucocorticoid-response elements in the 
promoter regions of cytokine genes, thereby blocking T cell-mediated cytokine expression. 
Thus, corticosteroids have been a mainstay of treatment during the early days after 
transplantation, but as immunosuppressive agents they are often accompanied by many 
side-effects within a few years. Calcineurin inhibitor is the first routinely employed 
immunosuppressive agent, including cyclosporine A (CyA) and tacrolimus (FK-506). CyA 
selectively inhibits T lymphocyte proliferation by forming a complex with cyclophilin. This 
complex can inhibit the calcium and calmodulin-dependent phosphatase calcineurin.  
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Fig. 9. Pattern of T cell activation and targeting of mainly immunosuppressors. Signals 1, 2 
and 3 for T cell activation are shown with a number. The drug targets used in tolerance 
protocols are shown with blue arrow 
Calcineurin is a key enzyme involved in controlling the transcription of IL-2 and other 
cytokines (Friman S et al., 1996). Therefore, impairing IL-2 transduction has a profound 
effect on the immune process of rejection by inhibiting calcineurin. However, the CyA 
metabolism is complex in liver transplant patients. Because it is metabolised primarily in the 
intestine and the liver, it increases the burden on the liver and even results in liver failure. 
Fk506 is very similar in action to CyA, but it is substantially more potent. It acts by binding 
to the FK-binding protein 12. The complex formed inhibits calcineurin, which regulates the 
transcription of the genes encoding IL-2, IL-3, IL-4, IL-8, as well as various chemotactic 
factors (Komolmit P et al., 1999). The side-effects of Fk506 are similar to those of CyA. In 
clinical practice, given the initial impairment of liver function and the frequent renal failure 
observed in the postoperative period, physicians should delay the administration of CyA or 
FK-506, with no impact on the outcome of liver transplantation or the occurrence of allograft 
rejection. Antimetabolites were not initially used in liver transplantation. Mycophenolate 
mofetil (MMF) – as a new antimetabolite molecule – has been shown to inhibit T and B cell 
proliferation, making it possible to reduce the rate of acute rejection in renal transplantation. 
These antimetabolites can be used together with an antibody against the IL2 receptor, 
delaying the introduction of CINs. These findings rapidly led to the use of these drugs in 
liver transplantation. Combination therapy with tacrolimus and MMF may significantly 
reduce the incidence of acute liver allograft rejection, allow a significant reduction in 
tacrolimus dosage, and decrease the incidence of nephrotoxicity (Eckhoff D E et al., 1998). In 
addition, the side-effects of MMF were relatively few. Inhibitors of TOR mainly include 
Rapamicine and Everolimus. Rapamicine is a macrocyclic triene antibiotic that is 
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structurally similar to tacrolimus. It forms a complex with the FK506-binding protein but it 
does not inhibit calcineurin. The complex blocks the cytokine response to T cell and B cell 
activation, preventing cell cycle progression and proliferation. Its principal side-effects are 
leukopenia, thrombocytopenia, high serum cholesterol and triglyceride levels, anaemia, 
lymphocele, wound dehiscence and mouth ulcers (Levitsky J., 2011). The biggest advantage 
of Rapamicine is associated with the lack of any significant nephrotoxicity (Vivarelli M et al., 
2010). Compared with Rapamicine, Everolimus has greater bioavailability and a shorter 
half-life. The antibodies used in transplantation may be monoclonal or polyclonal. At 
present, monoclonal antibodies primarily include IL-2R antibodies and anti-CD52 
antibodies. Two humanised IL-2R antibodies have been put on the market: basiliximab and 
daclizumab, which inhibit T cell proliferation by the competitive antagonism of IL-2-
induced T cell proliferation, and they are accompanied with very few side-effects. OK3 is 
also currently the most widely-used monoclonal antibody, which binds to part of the T cell 
receptor (CD3) complex. The major impact of OK3 has been in the reversal of steroid-
resistant, acute rejection (Cosimi A B et al., 1981). Polyclonal antibodies are IgG fractions 
from animals inoculated with human lymphocytes, thymocytes or cultured lymphoblast. 
Polyclonal antibodies have more profound and long-lasting biological depleting effects than 
other antibodies (Rebellato L M). However, polyclonal antibodies often induce the over-
suppression of the immune system, increasing the risk of infectious diseases, 
lymphoproliferative syndrome and tumours. 
There are significant variations in the regimens for immunosuppressive therapy used by 
different liver transplant centres. In general, most regimens include corticosteroids plus one 
calcineurin inhibitor, such as CyA or FK506. Anti-proliferative agents are often used in the 
first few months, with the patients also receiving bitoherapy with low doses of CIN and 
steroids. In liver transplantation, physicians tend to withdraw steroids within a few years 
due to their many side-effects. In addition, a study compared two groups of patients, one 
given induction therapy based on anti-thymocyte globulin (ATG) and FK506 without 
steroids, and the other treated with FK506, MMF and steroids. A graft survival of one-and-a-
half years was 89% in both groups. However, rejection-rates were significantly lower in the 
group that was treated without steroids than in the group that was treated with steroids 
(Eason JD et al., 2001). Calcineurin inhibitor treatment often caused renal failure by 
nephrotoxicity. Studies have shown that up to 21% of patients were found to have 
developed chronic renal failure within five years of receiving a non renal transplant (Ojo AO 
et al.,2003). A recent report has shown that Sirolimus-based immunosuppressive therapy is 
a safe, effective replacement agent for primary immunosuppressive therapy in liver 
transplant recipients with FK506-related chronic renal insufficiency (Yang YJ et al., 2008). 
Furthermore, the addition of MMF to the regimen, and the reduction of the dose of 
calcineurin inhibitor by more than 50%, has been shown to improve renal function. 
5.3 Prospective of using recipients T regulatory cell 
In fact, the immunosuppression regimens used in liver transplantation were historically 
derived from those used in renal transplantation. Immunosuppressive regimens are 
required to control the allogeneic response in clinical liver transplantation, but they may 
also lead to severe complications, such as infectious diseases, cancers, cardiovascular 
diseases and – for treatments involving calcineurin inhibitors – chronic renal insufficiency.  
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T regulatory cells (Tregs), a subset of CD4+CD25+Foxp3+ lymphocytes, have the functional 
ability to suppress alloimmune responses both in vitro and in vivo. Increasing evidence from 
animal transplant research shows that Tregs can play a key role in promoting 
immunological unresponsiveness to allograft transplants (Pilat N et al., 2010; Webster KE et 
al., 2009). Regulatory T cells are the key cell-types in the induction of immune tolerance, and 
so the modulation of such cells may provide new strategies in creating transplant tolerance. 
However, there are several challenges to translating Tregs into the clinic. Tregs only account 
for about 5-10% of the total CD4+ T cells in the periphery, the limitation of cell number 
restricted the clinical application. There are a number of studies demonstrating the 
functional instability of Tregs in vivo, which can become IL-17 producing T effector cells in 
the presence of IL-6 (Yang XO et al., 2008). Furthermore, T effector cells activated under 
inflammatory conditions are highly resistant to Tregs-mediated suppression (Korn T et al., 
2007). Concerning the Tregs, there are two broad approaches to the use of Tregs to promote 
transplant tolerance. The first is to expand Tregs in vitro and then apply expanded Tregs as a 
cell therapy in vivo. The advantage of this approach is that antigen-specific Tregs can be 
created in vitro using donor antigens. The second approach is to selectively and specifically 
stimulate in vivo, by taking advantage of fundamental differences between the biology of 
Tregs and T effector cells. In general, Tregs are a promising substance for the achievement of 
transplant tolerance.  
6. Conclusion 
The remarkable success of liver transplantation over the last four decades is due largely to 
the development of immunosuppressive regimens that are highly effective in protecting 
allografts from acute rejection, and that ensure their survival with a high quality of life in 
most cases. However, current immunosuppressive regimens do not prevent the 
development of chronic rejection, which constitutes a major cause of graft loss. In addition, 
these regimens may also lead to severe complications. This chapter mainly describe s the 
basic concepts of transplant immunology, the immunological basis of allograft rejection and 
the prevention and treatment of allograft rejection. In general, the immunological system of 
liver transplantation is very complex, and allograft tolerance has been well-established in 
experimental transplantation models; however, clinical operational tolerance will need to be 
further developed. Fortunately, Tregs may constitute a promising substance for achieving 
clinical operational tolerance by various modes of analysis. Furthermore, the clinical 
assessment of tolerance has been limited to laboratory-based evaluations of liver function 
and immunosuppressive agents’ levels, and more precise clinical assessments should have 
been well-established.  
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